To ensure correct antibiotic treatment and reduce the unnecessary use of antibiotics, there is an urgent need for new rapid methods for species identification and determination of antibiotic susceptibility in infectious pathogenic bacteria. We have developed a general method for the rapid identification of the bacterial species causing an infection and the determination of their antibiotic susceptibility profiles. An initial short cultivation step in the absence and presence of different antibiotics was combined with sensitive species-specific padlock probe detection of the bacterial target DNA to allow a determination of growth (i.e., resistance) and no growth (i.e., susceptibility). A proof-of-concept was established for urinary tract infections in which we applied the method to determine the antibiotic susceptibility profiles of Escherichia coli for two drugs with 100% accuracy in 3.5 h. The short assay time from sample to readout enables fast appropriate treatment with effective drugs and minimizes the need to prescribe broad-spectrum antibiotics due to unknown resistance profiles of the treated infection.
O
verprescription and extensive use of antibiotics have selected for resistant bacteria at an alarmingly rapid rate, and we are now facing one of the greatest medical challenges of our time (1) . Today, both the diagnosis of bacterial infections and determination of antibiotic susceptibility profiles (ASP) are slow and tedious processes. As a consequence, a patient might be given an antibiotic that has no effect on infections caused by resistant bacteria. Thus, there is a considerable need for new techniques enabling quick and specific diagnosis along with characterization of an ASP in order to guide correct treatment, reduce the use of broad-spectrum antibiotics, and slow the development of resistance.
In the last few decades, we have seen an amazing development of novel molecular methods to detect bacterial pathogens and their resistance genes and resistance mutations (2) (3) (4) (5) . These new hybridization/PCR-based methods are generally faster and more sensitive than are the classical phenotypic methods, but they also suffer from serious drawbacks that have often reduced their general use. An intrinsic limitation of all genotypic methods that identify resistance mutations or genes is that they detect only the potential for resistance (i.e., presence of a resistance gene/mutation), whereas phenotypic methods detect the realization of susceptibility (i.e., no growth in the presence of antibiotic). For a clinician, the realization of susceptibility measure is far more relevant as a basis for a therapeutic decision.
Padlock probes are oligonucleotides with target-specific ends, which upon perfect target recognition can be enzymatically joined (6) . Reacted probes can be amplified by rolling circle amplification (RCA). RCA is a linear amplification technique for the replication of DNA circles, such as reacted padlock probes, and the product is a single-stranded DNA concatemer containing around 1,000 copies of a 100-mer template circle after 1 h of replication (7, 8) . After monomerization by restriction enzymes, these products can be religated and further amplified by a second round of RCA (9) . The amplification products are typically labeled with fluorescence and detected by fluorescence microscopy or with a scanner (10, 11) .
In order to develop a general and quick method for both the diagnosis of infection and the generation of a corresponding ASP, we merged the classical growth-based phenotypic test with a highly sensitive and specific genotypic test to examine the resistance profile in a bacterial sample. With this method, a sample is cultivated for a short period in the absence and presence of different antibiotic substances. To detect growth or no growth, the sample DNA is harvested and exposed to padlock probes designed to detect target sequences positioned in the 16S rRNA region. The reacted probes are amplified by RCA, and the RCA products are counted in a high-performance fluorescence detector, providing precise digital quantification for the sensitive detection of differences in the DNA copy number. An increase in the DNA amount in the presence of the tested drug shows that the bacteria are phenotypically resistant; conversely, no growth in the presence of a drug indicates susceptibility. We demonstrate here the specificity of each padlock probe to its respective target, and we illustrate the performance of the method by determining the ASP for E. coli, which was the most common infectious agent in urinary tract infections (UTI) in 88 clinical samples in one retrospective and one prospective study. The time from urine sample to readout is 3.5 h, and therefore, this method has a significant time advantage compared to the commonly used culture-based methods.
MATERIALS AND METHODS
Rationale for the assay. The rationale for the assay is schematically outlined in Fig. 1 and includes four central steps: (i) growth in the absence and presence of different relevant antibiotics, (ii) total DNA preparation, (iii) species-specific padlock probe ligation and amplification, and (iv) digital readout of amplified reacted probes to assess any change in the quantity of rRNA genes in the absence and presence of antibiotics. The reaction chain begins with a short (30 min to 2 h) cultivation of a urine sample supplemented with LB (Fig. 1A) . This step distinguishes a susceptible strain from a resistant strain, as only bacteria with a resistant phenotype can grow in the presence of the antibiotic and thereby generate more genomes (rRNA genes). Genomic DNA was extracted from the cells by using NaOH and heat treatment to lyse the cells. Heat treatment also served to randomly fragment and denature the genome prior to padlock probe hybridization (Fig. 1B) . This crude cell lysate in urine/LB was used as input for the molecular assay without the need for purification.
Padlock probes were designed to target species-specific sequences in the 16S RNA genes of E. coli, Pseudomonas aeruginosa, and Proteus mirabilis (Table 1) . To enrich for the target sequences, the cell lysates were mixed with complementary biotinylated capture oligonucleotides and streptavidin-coated magnetic beads (Fig. 1C) . These served as a solid support and allowed the exchange of the urine/LB with the ligation mixture containing the padlock probes. Hybridized and ligated padlock probes were amplified by RCA ( Fig. 1D and E) and digested by restriction enzymes (Fig. 1F) . The monomers were religated for a second round of RCA to further increase the number of RCPs. Two oligonucleotides complementary to the RCA products and labeled with 5=-Cy3 were hybridized to the RCP during the second round of amplification (Fig. 1G) . A commercially available high-performance fluorescence detector (Aquila 400; Qlinea AB, Sweden) was used, since it allows for a fast and precise digital readout with a high dynamic range and quantitative precision. If necessary, the samples were diluted prior to measuring.
Processing of urine samples. We analyzed 88 urine samples from patients with UTI symptoms that were sent to the Uppsala University Hospital for analysis. All samples were routinely handled, anonymously, according to the Uppsala University Hospital rules. For the pilot study, samples were chosen that either showed no growth on agar plates, had a low colony count but did not classify as a UTI, or were positive for E. coli. For the positive samples, we analyzed only samples that were either susceptible for the tested antibiotics or were resistant to either ciprofloxacin or trimethoprim. All samples were collected in sterile transport tubes and transported and refrigerated for storage. One microliter was plated onto chromID CPS plates (bioMérieux SA, Marcy l'Etoile, France) and on horse blood agar plates. The CPS plates were incubated at 35°C under aerobic conditions, and the horse blood agar plates were incubated at 35°C in a CO 2 environment. A disk diffusion test (Oxoid Limited/Thermo Fisher Scientific, Waltham, MA, USA) was performed for all samples.
Sample pretreatment. For the spiked samples, 100 l of Luria-Bertani broth (LB) inoculated with the relevant laboratory strains (E. coli, P. aeruginosa, and P. mirabilis) were added to a 96-well plate and cultured at 37°C under aerobic conditions. For the patient samples, 10 l of urine and 90 l of LB were added to a 96-well plate. Each sample was split into triplicate (duplicate for patient samples) and either normal LB or LB supplemented to a final concentration of 0.5 g/ml ciprofloxacin or 4 g/ml trimethoprim was added. Due to the delay of growth inhibition of some antibiotics and the potential lag phase of the bacteria obtained from the clinical samples, we chose a culture time of 120 min prior the molecular test. After incubation, 10 l of 5 M NaOH was added to lyse the cells, To initiate the RCA reaction, the washing buffer was replaced with a mixture containing 25 nM primer, 0.2 g/l BSA, 125 M dinucleoside triphosphates (dNTPs), 1ϫ phi29 DNA polymerase reaction buffer (33 mM Tris-acetate [pH 7.9], 10 mM Mg-acetate, 66 mM K-acetate, 0.1% Tween 20, 1 mM DTT; Thermo Scientific), and 100 mU/l phi29 DNA polymerase (Thermo Scientific); the mixture was incubated at 37°C for 20 min, followed by an inactivation step at 65°C for 1 min. The rolling circle products (RCPs) were digested by adding 5 l of 0.2 g/l BSA, 1ϫ phi29 DNA polymerase reaction buffer, 600 mU/l AluI (New England BioLabs), and 600 nM restriction oligonucleotide, which was incubated at 37°C for 1 min, followed by 65°C for 1 min. To start a second round of RCA and simultaneously label the RCPs, 25 l of 0.2 g/l BSA, 1.36 mM ATP, 28 mU/l T4 DNA ligase (Thermo Scientific), 1ϫ phi29 DNA polymerase reaction buffer, 10 nM each of the three detection oligonucleotides, and 120 mU/l phi29 DNA polymerase were added and incubated for 20 min at 37°C and 1 min at 65°C. The patient samples were diluted 1:100 in a labeling buffer (25 nM detection oligonucleotide 1, 25 nM detection oligonucleotide 2, 25 nM detection oligonucleotide 3, 10 mM EDTA, 10 mM Tris-HCl [pH 7.5], 0.25% Tween 20, and 0.5 M NaCl). The processed samples were analyzed in a high-performance fluorescence detector (Q-linea AB, Uppsala, Sweden) that digitally counts the RCPs. The biotinylated Alexa 488-conjugated detection oligonucleotide 3 was added for better discrimination between the magnetic beads and RCPs. If the counts were Ͼ1,000,000, an additional 1:10 dilution in labeling buffer was performed, and the samples were measured again.
RESULTS

Detection of growth inhibition.
In order to evaluate whether bacterial growth could be measured by this approach, and at what sensitivity, a growth curve was established by inoculating LB medium with E. coli to a final concentration of 10 4 CFU/ml and culturing for 120 min; measurements were taken every 30 min to determine the sensitivity of our assay (Fig. 2) . The negative control (LB medium without bacteria) was incubated for 90 min under the same conditions as those of the spiked cultures. We selected a bacterial load that is similar to the commonly used limit to define a clinical infection in otherwise healthy individuals (12) . A viable plate count on Luria-Bertani agar plates was done for each time point in parallel. Our results showed that under these controlled conditions, DNA synthesis is already detectable after 30 min, whereas bacterial growth using viable plate count can be detected after 90 min at the earliest.
Specificity. The padlock probes in this study were designed to target three different uropathogenic bacteria: E. coli, P. aeruginosa, and P. mirabilis. To test species specificity, three padlock probes were combined with the three target bacterial strains (10 6 CFU/ ml), resulting in a matrix of nine combinations. This experiment revealed that all padlock probes were exclusively detecting their respective target and there were no unspecific signals over background (Fig. 3) .
Antibiotic susceptibility profile. In order to test whether it is possible to establish an ASP with our approach, three strains of E. coli (Table 2) were exposed to either ciprofloxacin (0.5 g/ml) or trimethoprim (4 g/ml) and cultured for 2 h in Luria-Bertani (LB) broth. These antibiotics were chosen because both are widely used in Sweden. Ciprofloxacin is used for the treatment of complicated UTIs, and, until recently, trimethoprim was used as a first-line agent. The antibiotic susceptibility test was based on four samples per test (Fig. 4A) . Sample x 1 was taken before culture without antibiotics, sample x 2 after culture without antibiotics, sample y 2 after culture in medium with ciprofloxacin, and sample z 2 after culture in medium with trimethoprim. Growth was calculated as follows: X ϭ x 2 Ϫ x 1 for growth in the absence of antibiotics, Y ϭ y 2 Ϫ x 1 for growth in the presence of ciprofloxacin, and Z ϭ z 2 Ϫ x 1 for growth in the presence of trimethoprim. To quantify relative growth, the ratio of the growth signals from antibiotic-containing and non-antibiotic-containing samples was calculated. For ciprofloxacin, Y/X was calculated, and Z/X was calculated for trimethoprim. As shown in Fig. 4B , wildtype (WT) and trimethoprim-resistant (Tmp r ) E. coli did, as expected, not grow in the presence of ciprofloxacin. The ciprofloxacin-resistant strain (Cip r ) grew well in the presence of ciprofloxacin. There was minor growth of the WT and ciprofloxacinresistant (Cip r ) E. coli strains in the presence of trimethoprim but below the threshold that would give a positive signal in the molecular test. As expected, the Tmp r strain grew well in the presence of trimethoprim (Fig. 4B) .
To demonstrate that our approach is capable of detecting and determining the ASP of coinfections, samples containing more than one bacterial species (10 4 CFU/ml of each species) were cultured for 120 min. Subsequently, our molecular assay was performed on all samples, and relative growth was calculated as described above. In total, we tested four different combinations of bacterial species. 5 cells of three species (E. coli, P. aeruginosa, and P. mirabilis) were inoculated into LB and exposed to padlock probes (PLP) designed to specifically target each of these three species. The y axis displays the number of RCPs counted in a 100-s measurement. The error bars indicate Ϯ1 SD; n ϭ 3. (Fig.  5D) . The absence or presence of a bacterial species was correctly identified in all four samples. Moreover, we were able to establish the correct ASP for all detected bacteria.
Patient samples. To empirically determine the thresholds for an E. coli-positive UTI infection and for antibiotic resistance to ciprofloxacin and trimethoprim, a retrospective study material was selected to include a number of E. coli-negative cases, along with positive cases, of both Cip-and Tmp-susceptible and -resistant cases. This training set of samples for the diagnostic algorithm was selected from samples previously tested and profiled for antibiotic susceptibilities by a culture-based disk diffusion assay at the Uppsala University Hospital in Sweden. The samples that were Յ3 days old were chosen for our pilot study, which was the minimum amount of days required to obtain the clinical E. coli UTI diagnosis and ASP.
Our diagnostic procedure was performed according to the test setup described above (Fig. 4) . From these first 32 tested samples (U-1 to U-33), we developed an algorithm to classify the patient samples. The algorithm is described below and in the flowchart displayed in Fig. 6 . For a UTI sample to be considered E. coli positive, a signal of Ն4,000 RCPs after culture without antibiotics was required. A reliable ASP was established only if growth was Ͼ7,000 RCPs in the absence of antibiotics. The cutoff for resistance was set to 30% relative growth for both trimethoprim and ciprofloxacin. The samples with a lower relative growth were clas- sified as susceptible. With these criteria, all 32 samples were correctly diagnosed with respect to E. coli UTI. The determination of an ASP was possible, according to our diagnostic algorithm, for 31 out of the 32 samples. These 31 samples were all correctly classified and showed the same resistance profiles as those derived from a traditional culture-based disk diffusion test (Table 3 and Fig. 7A ). In summary, we achieved a correct ASP for all 31 samples that passed our criteria for establishing ASP.
To verify the developed algorithm for the classification of urine samples, we conducted a blind prospective validation study that encompassed 56 urine samples (U-35 to U-90). All samples were tested with our assay and, in parallel, routinely analyzed in a clinical setting. The presence or absence of E. coli was correctly identified in 55 out of 56 samples, with no false positives (the exception had a level of bacteria below the threshold level of 10,000 CFU). Furthermore, we determined the correct ASP for all samples in which E. coli was detected above threshold levels, and the resistance profiles were identical to those determined by the clinical laboratory using the disk diffusion assay. Of the 56 samples, 45 were E. coli negative, and among the E. coli-positive samples, 9 were Tmp susceptible, 9 were Cip susceptible, 2 were Tmp resistant, and 2 were Cip resistant. Based on this sample set, we have validated the thresholds obtained in the pilot study and developed an assay that showed 100% specificity and 100% sensitivity. A correct ASP was also established in samples having a coinfection with a second pathogen. The presence of other bacteria, such as P. mirabilis, Enterococcus faecalis, or Gram-positive mixed flora, did not affect the accuracy of this assay, which showed 100% specificity toward E. coli (Table 3 and Fig. 7B ).
DISCUSSION
We present here a new concept for diagnosing and screening bacteria for ASP based on the combined information from culture in the absence and presence of antibiotics and highly sensitive species-specific detection of 16S rRNA gene sequences. The method is robust, accurate, and fast. All of these aspects are central properties of a potential diagnostic instrument for the clinic. Since the padlock probes identify only bacterial species and not the resistance genes, the antibiotic susceptibility profiling is independent of genotype and resistance mechanism. This also means that new antimicrobial compounds could easily be added to the assay without the need to design new padlock probes. The specificity of the padlock probes also renders this assay suitable for analyzing more complex samples, as demonstrated by the correct diagnosis of samples with coinfections or the presence of Gram-positive mixed flora. This is in principle a general method, and our approach is not limited to UTIs, but it could be extended to other types of infections, such as sepsis and respiratory infections. Another major advantage of our assay is the ability to use patient samples directly without the need for any purification, as might be required for PCR (since many body fluids contain PCR inhibitors) (13) . The clinical validation study was small, but of the 56 samples that passed our criteria for establishing ASP, 100% were correctly profiled, which is identical to the results of the routine diagnostic test. Similarly, in the pilot study, both the routine diagnostic test and our test determined the ASP with 100% accuracy. We failed to detect one out of 56 samples. This sample, however, contained only 10,000 E. coli CFU/ml, which is considered to be below the limit for an UTI (14) .
To be applicable to a wider range of infectious samples and bacterial species, certain method modifications would be necessary. For species with much lower growth rates, longer incubation times would be needed. Similarly, in samples with low bacterial loads (e.g., blood samples), the sensitivity would need to be improved by both longer incubation times and an extension of the RCA time. Furthermore, for certain classes of antibiotics, such as ␤-lactams, which act more slowly to stop bacterial growth compared to the ones used in this study, an increased culture time would be necessary. Finally, for efficient use in a clinical laboratory, it is required that the method can be fully automated. One example of microfluidic automation has been described in Küh-nemund et al. (15) , and major steps in other microfluidic approaches are in development (A. Ahlford, I Hernandez-Neuta, and T. Salih, unpublished data). There is also a commercially available instrument for automation (Aquila 1000; Q-linea, Sweden). This instrument provides full automation of all the reaction steps described here from the lysed sample to digital readout. In this study, we established ASP for only two antibiotics, which required the distribution of urine samples to three tubes for culture, as well as four samples from culture for analysis (two from the culture without antibiotics and one each for the antibioticcontaining cultures). Expansion of the assay to a larger panel of antibiotics will require one more culture tube per antibiotic and concentration, which is trivial with an automated system. Additional pathogen species can be targeted either by adding more parallel analysis reactions with specific padlock probes or by multiplexing of several padlock probes in the same reaction, using a dual-or triple-color readout system.
The current commercially available antibiotic susceptibility test (AST) instruments, such as Vitek 2, can produce AST results in Ͻ5 h. An inoculum can be obtained directly from urine samples, in contrast to the usual inoculation on chromogenic agar medium. However, the correct identification rate by that method is only 82.3% (16) , which is significantly lower than that of our method. Other methods for ASTs have also been developed using microfluidics (17, 18) , but in contrast to our method, these methods not only lack species identification, but they also require an overnight culture. Thus, the abovementioned assays provide less information and take longer time than the assay presented here. Recently, Mach et al. (19) demonstrated a rapid AST method that detects an increase in 16S rRNA by measuring an electrochemical output signal, with a reported assay time of 3.5 h. However, the assay had a limit of detection of 5 ϫ 10 5 CFU/ml, making it difficult to successfully test patient samples with a low bacterial load.
